Sunshine Biopharma Inc
NASDAQ:SBFM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sunshine Biopharma Inc
EPS (Diluted)
Sunshine Biopharma Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sunshine Biopharma Inc
NASDAQ:SBFM
|
EPS (Diluted)
-$1
|
CAGR 3-Years
80%
|
CAGR 5-Years
65%
|
CAGR 10-Years
67%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
EPS (Diluted)
-CA$1
|
CAGR 3-Years
34%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
EPS (Diluted)
$2
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
EPS (Diluted)
-$4
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-15%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
EPS (Diluted)
CA$0
|
CAGR 3-Years
7%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
EPS (Diluted)
-$2
|
CAGR 3-Years
-22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sunshine Biopharma Inc
Glance View
Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. The company is headquartered in Pointe-Claire, Quebec and currently employs 3 full-time employees. The company went IPO on 2008-08-15. In addition, the Company is engaged in the development and commercialization of science-based nutritional supplements. The Company’s drug development operations include SBFM-PL4 Anti-Coronavirus Treatment and Adva-27a Anticancer Drug. The firm is engaged in the development of its Anti-Coronavirus compound, SBFM-PL4. The company is advancing the development of two compounds in parallel with its SBFM-PL4. The Company’s drug development activities have focused on the development of a small molecule, Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells, including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells.
See Also
What is Sunshine Biopharma Inc's EPS (Diluted)?
EPS (Diluted)
-1.4
USD
Based on the financial report for Dec 31, 2025, Sunshine Biopharma Inc's EPS (Diluted) amounts to -1.4 USD.
What is Sunshine Biopharma Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
67%
Over the last year, the EPS (Diluted) growth was 80%. The average annual EPS (Diluted) growth rates for Sunshine Biopharma Inc have been 80% over the past three years , 65% over the past five years , and 67% over the past ten years .
